[Hematologic tumors].
Hematologic tumors are commonly systemic on diagnosis, and chemotherapy is therefore the sole method by which to obtain a prolongation of survival or cure. Based upon results from a prospective randomized trial compared to a combination regimen consisting of daunorubicin and cytarabine, the first line chemotherapeutic regimen for acute myelogenous leukemia is considered to be a combination regimen consisting of idarubicin and cytarabine. The standard chemotherapeutic regimen for advanced Hodgkin's disease would seem to be an ABVD regimen, judging from results reported from a prospective randomized trial which compared MOPP, ABVD and MOPP-ABVD. The first generation combination CHOP is recognized as a standard regimen for advanced non-Hodgkin lymphoma due to results of a prospective randomized trial compared with intensive chemotherapeutic regimens.
Ogawa
M
M
Aichi Cancer Center.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000592:standards* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy